Allosteric Interactions in Receptor Binding Studies

  • N. J. M. Birdsall
  • E. C. Hulme
  • J. Stockton
  • M. J. Zigmond
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 13)


Receptor binding studies can not only detect the competitive interaction of drugs with the binding site for a radiolabeled drug, but also render it possible to monitor the binding of ligands to secondary sites which are allosterically linked to the primary binding site. These modulatory ligands can produce their effects by interacting with a second site on the receptor protein or on other proteins which interact specifically with the receptor. It is possible to obtain information about receptor-effector coupling mechanisms as well as to detect binding sites for drugs which could have novel pharmacological profiles.


Adenylate Cyclase Fixed Concentration Primary Binding Site Receptor Binding Study Allosteric Interaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Olsen, R.W. (1982) Ann. Rev. Pharmacol. Toxicol. 22, 245–277.CrossRefGoogle Scholar
  2. 2.
    Study, R.E. & Barker, J.L. (1981) Proc. Nat. Acad. Sci. 78, 7180–7184.CrossRefGoogle Scholar
  3. 3.
    Möhler, H. & Richards, J.G. (198l) Nature 294, 763–765.CrossRefGoogle Scholar
  4. 4.
    Braestrup, C., Schmiechen, R., Neef, G., Nielsen, M. & Petersen, E.N. (1982) Science 216, 1241–1243.CrossRefGoogle Scholar
  5. 5.
    Stockton, J.M., Birdsall, N.J.M., Burgen, A.S.V. & Hulme, E.C. (1983) Mol. Pharmacol., in press.Google Scholar
  6. 6.
    Roszkowski, A.P. (1961) J. Pharm. Exp. Ther. 132, 156–170.Google Scholar
  7. 7.
    Birdsall, N.J.M., Burgen, A.S.V., Hulme, E.C., Stockton, J.M. & Zigmond, M.J. (1983) Br. J. Pharmacol. 78, 257–259.CrossRefGoogle Scholar
  8. 8.
    Maguire, M.E., van Arsdale, P.M. & Gilman, A.G. (1976) Mol. Pharmacol. 12, 335–339.Google Scholar
  9. 9.
    Berrie, C.P., Birdsall, N.J.M., Burgen, A.S.V. & Hulme, E.C. (1979) Biochem. Biophys. Res. Comm. 87, 1000–1004.CrossRefGoogle Scholar
  10. 10.
    Hulme, E.C., Berrie, C.P., Birdsall, N.J.M. & Burgen, A.S.V. (1981) Eur. J. Pharmacol. 73, 137–142.CrossRefGoogle Scholar
  11. 11.
    Adams, P.R. (1977) J. Physiol. 268, 291–318.Google Scholar
  12. 12.
    Shaker, N., Eldefrawi, A.T., Aguayo, L.G., Warnick, J.E., Albuquerque, E.X. & Eldefrawi, M.E. (1982) J. Pharmacol. Exp. Ther. 220, 172–177.Google Scholar
  13. 13.
    Colquhoun, D., Dreyer, F. & Sheridan, R.E. (1979) J. Physiol. 293, 247–284.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • N. J. M. Birdsall
    • 1
  • E. C. Hulme
    • 1
  • J. Stockton
    • 1
  • M. J. Zigmond
    • 1
  1. 1.Division of Molecular PharmacologyNational Institute for Medical ResearchLondonUK

Personalised recommendations